Company intelligence / Profile preview

Resilience Government Services

Alachua, Florida, United States

Ownership: Private
Development stage: Other

Overview

The company, through its advanced biologics manufacturing facilities, has produced clinical and commercial supplies for government programs including monoclonal antibodies for botulism and COVID-19, with some programs progressing to Phase 2 trials and others supplying critical medical countermeasures for national security[2].

Therapeutic areas: ImmunologyInfectious Diseases
Modalities: Monoclonal antibodyDNA vaccineInactivated viral vaccineRecombinant proteinPlasmid DNAProtein
Industry: Contract Manufacturing Organization

Partnerships

Department of Defense (DoD)Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND)Defense Threat Reduction Agency (DTRA)

Beyond the preview

Go deeper on Resilience Government Services.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Resilience Government Services.

Explore the full profile